INTRODUCTION
Hemorrhage decreases blood flow to the intestine and is followed by rapid intestinal damage and inflammation, which may initiate a systemic inflammatory response (1) (2) . The intestinal inflammatory response involves multiple components of the innate immune system including neutrophils, complement and cytokines (3) (4) (5) . Hemorrhage-induced inflammation also includes activation of macrophages within the liver, spleen and lungs (6) (7) (8) . However, the specific complement activation pathway and the early intestinal effects on macrophage infiltration and activation in response to hemorrhage are not well defined.
Comprised of more than thirty proteins in the blood, complement protects the body by removing pathogenic microorganisms. Initiated by multiple pathways, complement activation generates C3 opsonins, chemotactic peptides and the cytolytic terminal membrane attack complex. Antibody or lectin deposition on surface membranes initiates the classical and lectin pathways, respectively. The spontaneously activated, alternative pathway amplifies the classical and lectin pathways. However, excessive complement activation increases susceptibility to infections (9) and the amplification induced by the alternative pathway increases pathology in multiple disease states (10) (11) . Treatment with complement inhibitors, C5a receptor antagonist (3) or cobra venom factor (12) , attenuated hemorrhage-induced intestinal damage without identifying the specific initiation pathway. It is likely that the alternative pathway either directly or by amplification contributes to hemorrhage-induced tissue damage. During excessive or inappropriate complement activation, natural inhibitors protect host cells and tissues. Factor H (fH) binds C3b, preventing or dissociating the alternative C3 convertase and the subsequent amplification loop. By inhibiting amplification of the classical and lectin pathways, fH is a logical therapeutic for excessive complement activation. In other disease models, complement receptor 2 (CR2) targeted fH significantly enhanced the effectiveness of fH by targeting the inhibitor to sites of complement activation (13) .
Hemorrhage induces neutrophil and macrophage infiltration into the hypoxic intestine (12, 14) .
Multiple studies indicated that a neutrophil response with oxidative burst is critical to hemorrhage-induced damage (14) (15) . Hemorrhage also activates Kupffer cells in the liver and macrophages in the spleen (6-7) to release cytokines. A recent study indicated that intestinal tissues release the macrophage inflammatory cytokines, tumor necrosis factor -a (TNF), and nitric oxide in response to hemorrhage (12) . In addition, inhibition of IL-6 (16) or TNF (17-18) attenuated hemorrhage-induced inflammation. However, a role of macrophage-produced IL-12 in the intestinal response to hemorrhage is not well characterized. The proinflammatory IL12p70 consists of 2 subunits, IL-12p40 and IL-12p35. IL-12p40 is also a subunit of IL-23, which stimulates Th17 cells. In addition, IL-12p40 homodimers directly antagonize both IL-12p70 and IL-23 (19). Therefore, hemorrhage-induced macrophage infiltration may control the inflammatory process through the production of specific IL-12 components.
We hypothesized that alternative complement activation interacts with macrophage secreted IL-12 and all three innate immune components are critical for hemorrhage-induced inflammation.
We show that administering the targeted complement inhibitor, CR2-fH, to mice following hemorrhage significantly decreases intestinal damage and inflammation by reducing macrophage infiltration and IL-12p40 production. Furthermore, macrophage depletion with clodronate, IL12p40 or IL-12p35 depletion attenuated injury and inflammation. In contrast, IL-23p19 depletion did not attenuate injury. Thus inhibition of the alternative complement activation pathway attenuates macrophage infiltration and IL-12p70 production during the hemorrhage-induced inflammatory response and provides multiple therapeutic targets within the innate immune response.
Materials and Methods:
Mice: C57Bl/6J male mice (6) (7) (8) Hemorrhage Protocol: After anesthetizing with ketamine (16 mg/kg) and xylazine (8 mg/kg), a drop of 0.5% proparacaine hydrochloride ophthalmic solution was applied to the appropriate eye.
Mice subjected to hemorrhage sustained removal of 25% total blood volume via the retro-orbital sinus as described previously (3, 20) . Blood volume removed was determined by weight (grams) using the following equation (~25% = wt x 0.02) (3, 20) and completed within five minutes.
Sham-treated mice were subjected to similar procedures with no blood removal. Body temperature of animals was maintained at 37 C using a water-circulating heating pad and all procedures were performed with the animals breathing spontaneously. Two hours after hemorrhage, mice were euthanized and sera and tissue collected. Mid-jejunal sections (2cm), approximately 10 cm distal to the gastroduodenal junction, were collected for histology and subsequent analyses. Additional mice underwent the same procedures as above with i.v. administration of CR2-fH (17.5uM) five minutes after bleeding. CR2-fH was produced as described previously (13) . Some mice received neutralizing anti-IL-12p40 (R&D Systems) or anti-IL-23p19 (R&D Systems) mAb (mg/kg) i.p. at 1 hr prior to hemorrhage.
Histology & Injury Score: After fixation in 10% buffered formalin, paraffin embedded tissue sections were cut transversely (8μm) and H&E stained for scoring mucosal injury. Using a sixtiered scale as described previously (21), the average damage score of mid-jejunum intestine (75-150 villi) was determined after grading each villus from 0-6 with the following categories:
Normal villi were assigned a score of zero; villi with tip distortion were assigned a score 1; a score of 2 was assigned when Guggenheims' spaces were present; villi with slight disruption of the epithelial cells were assigned a score of 3; a score of 4 was assigned to villi with exposed but intact lamina propria; a score of 5 was assigned when the lamina propria was exuding; last, villi that displayed hemorrhage or were denuded were assigned a score of 6.
Ex vivo secretions:
Ex vivo intestinal supernatants were generated as described previously (3, were fixed in cold acetone and non-specific binding was blocked using 10% donkey serum in PBS. Tissues were stained for C3 deposition using a rat-anti-mouse C3 antibody (Hycult Biotechnologies) followed by an appropriate secondary antibody (Jackson Immunoresearch) or for F4/80 using directly conjugated rat-anti mouse F4/80 (eBioscience). Serial sections stained with isotype control antibodies were used as background. Slides were examined by a blinded observer by fluorescent microscopy using a Nikon 80i fluorescent microscope and images acquired using a CoolSnapCf camera (Photometrics) and MetaVue Imaging software (Molecular Devices). 
RESULTS

CR2-fH attenuates hemorrhage-induced mucosal damage and inflammation.
We verified the ability of CR2-fH to inhibit complement activation by measuring serum C5a in wildtype C57Bl/6 and CR2-fH treated mice. As no significant difference was observed between Shams from different treatment groups or mouse strains, these data are shown as pooled Shams in all graphs. Similar to previous studies (3), serum from hemorrhaged C57Bl/6 mice contained significantly more C5a than Sham-treated mice (Fig. 1A) . In contrast, C5a was not significantly elevated in the serum of CR2-fH treated mice with or without hemorrhage (Fig. 1A) , indicating that CR2-fH attenuated hemorrhage-induced complement activation. Importantly, administration of CR2-fH significantly attenuated intestinal damage in response to hemorrhage (Table 1 and Fig. 1E-F) . CR2-fH treatment also attenuated the intestinal inflammatory response. Intestinal LTB 4 production was significantly elevated in hemorrhage-treated mice only in the absence of CR2-fH treatment (Fig. 1B) . In addition, at 2 h post hemorrhage, C57Bl/6 mice expressed significantly elevated levels of intestinal IL-12p40 and TNF-α, and CR2-fH treatment reduced these cytokine secretions to the level of Sham treated mice (Fig. 1C-D) . These data indicate that in a fixed-volume mouse model of hemorrhage, inhibition of the alternative complement pathway attenuates the early LTB 4 and cytokine response.
Macrophage depletion attenuates hemorrhage-induced intestinal damage and inflammation.
As the above cytokines may be produced by activated macrophages or epithelial cells, we To determine if macrophages are required in hemorrhage-induced intestinal injury, we subjected mice to hemorrhage after depletion of macrophages with Cl 2 MDP containing liposomes.
Immunohistochemistry confirmed macrophage depletion in Cl 2 MDP treated mice (Fig. 2D, G) .
As indicated in Table 1 , macrophage depleted mice did not sustain hemorrhage-induced intestinal injury when compared to mice treated with PBS containing liposomes. Similar to untreated mice, in response to HS, mice treated with liposomes containing PBS produced significant quantities of LTB 4 and IL-12p40 (3.2 ± 1.1 and 12 ± 1.11 pg/mg tissue, respectively).
After treating with liposomes containing Cl 2 MDP, hemorrhage induced significantly lower concentrations of intestinal LTB 4 and IL-12p40 (0.98 ± 0.13 and 4.6 ± 1.7 pg/mg tissue, respectively) compared to liposomes containing PBS. It was possible that macrophage depletion altered the mechanism of intestinal damage. Therefore, we examined C3 deposition in mice treated with liposomes containing PBS or Cl 2 MDP. Compared to Sham-treated mice, intestinal sections from mice pre-treated with PBS containing liposomes displayed more C3 deposition (Fig. 3A, B) . In contrast, C3 deposition was not detected on the intestinal tissue of macrophagedepleted mice (Fig. 3C) .
IL-12p35 RNA expression increases in response to hemorrhage.
IL-12 family members, IL-12p70 and Il-23, play a role in other models of intestinal damage (24) (25) (26) (27) . Using real time PCR, we evaluated IL-12p40, IL-12p35 and IL-23p19 mRNA to determine the critical family members. As indicated in Figure 4A , IL-12p40 mRNA was maintained within all treatment groups. In contrast, IL-12p35 was significantly elevated in response to HS in wildtype mice and in wildtype mice after treatment with PBS containing liposomes (Fig. 4B) .
However, treatment with fH-CR2 or macrophage depletion eliminated the HS increase in IL12p35 RNA (Fig. 4B) . Although IL-23p19 RNA expression increased with HS, complement inhibition only altered Il-12p35 RNA expression not production of IL-23p19 RNA expression (Fig. 4C) . Clodronate treatment eliminated hemorrhage-induced IL-12p40, IL-12p35 and IL23p19 RNA expression (Fig. 4) . These data suggest that HS induces macrophages to produce IL-12p70. hemorrhage-induced serum C5a compared to C57Bl/6 mice (138 ± 13 ng/ml and 194 ± 25 ng/ml, respectively). However, the hemorrhage-induced C5a levels in IL-12p40 -/-mice were significantly higher than Sham treated mice (76 ± 6 ng/ml). Thus, IL-12p40 -/-and Il-12p35 -/-mice are protected from intestinal damage with lower levels of complement activation than C57Bl/6 mice. Despite increased macrophage infiltration after hemorrhage (Fig 2E-F) , IL12p40 -/-and IL-12p35 -/-mice produced significantly less intestinal LTB 4 and TNF- than wildtype mice (Fig. 5A-B) .
To confirm that IL-12p70 and not IL-23 is a critical intestinal cytokine produced in response to HS, we administered either IL-12p40 or IL-23p19 neutralizing antibodies or isotype control antibodies to additional wildtype mice. As indicated in Table 1 (Table 1 and Fig. 5C ). Together these data suggest that macrophage production of IL-12p70 is critical for intestinal damage and inflammation.
Discussion
Although hypothesized to be the motor of systemic inflammation and subsequent mortality, intestinal damage and inflammation occurs rapidly (within 2 h) and repair occurs equally quickly (within 3-4 h) in the presence or absence of resuscitation (2, 12) . Previous studies concluded that the hemorrhage-induced response requires complement activation without identifying the specific activation pathway (3, 20, (28) (29) . The present study indicates that inhibition of the alternative complement pathway with CR2-fH attenuates mid-jejunal mucosal damage and Previous studies showed that systemic blockade of central complement components, C3, C5 or C5a, attenuated hemorrhage-induced intestinal damage (3, 30-31). However, each of these systemic inhibitors increases the risk of sepsis by blocking multiple complement activation pathways. CR2-fH binds tissue-bound C3 activation products and provides local but not systemic complement inhibition (13, 32) . In addition, when administered early after hemorrhage, CR2-fH effectively prevented hemorrhage-induced tissue damage and inflammation. These results are similar to the ability of CR2-fH to attenuate tissue damage in models of collagen induced arthritis, complement-dependent macular degeneration and direct intestinal ischemia/reperfusion (13, 32) . Treatment with CR2-fH also significantly decreased TNF- mRNA in arthritic joints (32), suggesting a decrease in macrophage cytokine production. We extended the antiinflammatory properties of CR2-fH to include significantly reducing macrophage infiltration and associated cytokines in response to hemorrhage. Although the specific mechanism is not known, the alternative complement activation pathway is critical for hemorrhage-induced intestinal damage and inflammation. In response to hemorrhage, the alternative complement activation pathway induces a macrophage infiltrate into the intestine and IL-12 secretion. These data indicate that all three components of the innate immune response are required for hemorrhage-mediated mid-jejunal damage. Thus, therapeutics targeting local alternative complement activation not only prevent complement mediated damage, but also attenuate macrophage activation and cytokine production. B6 HS+
